Royalty Pharma (RPRX) Other Non Operating Income (2019 - 2026)

Royalty Pharma has disclosed Other Non Operating Income across 8 years of filings, most recently posting -$1.5 million for Q2 2026.

• In Q2 2026, Other Non Operating Income rose 3.05% year-over-year to -$1.5 million; the TTM figure through Jun 2026 stood at -$7.9 million (up 25.82% YoY), while the FY2025 annual figure was -$14.3 million, down 139.15% from the prior year.
• Other Non Operating Income came in at -$1.5 million for Q2 2026 at Royalty Pharma, up from -$2.2 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $71.8 million in Q2 2022 to a low of -$18.3 million in Q4 2023.
• Average Other Non Operating Income over 5 years is $3.3 million, with a median of -$1.5 million recorded in 2025.
• Year-over-year, Other Non Operating Income soared 3861.39% in 2022 and slumped 1768.16% in 2023.
• Over 5 years, Other Non Operating Income stood at -$980000.0 in 2022, then tumbled by 1768.16% to -$18.3 million in 2023, then surged by 50.84% to -$9.0 million in 2024, then increased by 9.22% to -$8.2 million in 2025, then surged by 81.69% to -$1.5 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were -$1.5 million in Q2 2026, -$2.2 million in Q1 2026, and -$8.2 million in Q4 2025.